

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

18

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/481,572 01/11/00 SHAN

J P0061-9013

EXAMINER

HM12/1012
ARENT FOX KINTNER PLOTKIN & KAHN PLLC
1050 CONNECTICUT AVENUE NW
SUITE 600
WASHINGTON DC 20036-5339

MELLER, M

ART UNIT

PAPER NUMBER

1651

6

DATE MAILED:

10/12/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/481,572	Applicant(s) Shan et al.
Examiner Michael Meller	Group Art Unit 1651



Responsive to communication(s) filed on _____

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle 1035 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire three month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claim

Claim(s) 1-22 _____ is/are pending in the application

Of the above, claim(s) 18-21 _____ is/are withdrawn from consideration

Claim(s) _____ is/are allowed.

Claim(s) 1-17 and 22 _____ is/are rejected.

Claim(s) _____ is/are objected to.

Claims _____ are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) _____

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1651

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-17 and 22, drawn to a method of treating a health disorder using a compound, classified in class 424, subclass 1648D.
 - II. Claims 18-21, drawn to a compound, classified in class 424, subclass 195.1.
2. The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in a materially distinct process such as a herbicide.
3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
4. This application contains claims directed to the following patentably distinct species of the claimed invention: Hypericum perforatum, a Hypericum extract, an extract of a species of the

Art Unit: 1651

Hypericum genus other than Hypericum perforatum, a Hypericum constituent, a hypericin derivative, or a hypericin analog. The species also include the species of claims 2, 4-7, 13-17 and 22.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1651

5. During a telephone conversation with King Wong on 9/26/00 a provisional election was made with traverse to prosecute the invention of Group I, claims 1-17 and 22 and an election of species was made for an extract from *Hypericum perforatum*. Affirmation of this election must be made by applicant in replying to this Office action. Claims 18-21 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Rejections - 35 USC § 112

7. Claims 1-17 and 22 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is rejected since it presents an improper markush group. The elements in the markush group should be equivalent to each other and be in alternative form to one another. The use of "or" the end of the claim is improper. The claim should be written as follows, "A

Art Unit: 1651

method of treating using an active agent selected from the group consisting of x, y and z."

The same is true of claims 2-7.

The claim further is confusing since in claim 3, diabetes and ischaemic appear to be misspelled. What is meant by the term "brain aging" ? This has no art recognized meaning. Further, how can claim 3 include migraine headaches and depression when claim 1 excludes them ?

Claim Rejections - 35 USC § 102

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

9. Claims 1-17 and 22 are rejected under 35 U.S.C. 102(b) as being anticipated by DE 1692045, BE 654914 or EP 0847756, see abstract.

Each of these references teach an extract from *Hypericum perforatum* used to treat health disorders such as angina pectoris and hepatitis. Using the extract to treat hepatitis is considered to also treat health disorders such as angina pectoris since it is inherent that angina pectoris will also be treated. The method of using the extract is the same.

10. Claims 1-17 and 22 are rejected under 35 U.S.C. 102(e) as being anticipated by Lavie et al. (US 6,056,961), see abstract.

Art Unit: 1651

The reference teaches an extract from *Hypericum perforatum* used to treat hepatitis.

Using the extract to treat hepatitis is considered to also treat health disorders such as angina pectoris since it is inherent that angina pectoris will also be treated. The method of using the extract is the same.

Any inquiries concerning this communication should be directed to Examiner Mike Meller at telephone number (703) 308-4230. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Michael Wityshyn, can be reached at (703) 308-4743. The Fax phone number for the art unit is (703) 308- 0294. Any inquiries of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.



Christopher Tate
Patent Examiner